Every Form 4 that Exponent Inc (EXPO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow EXPO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EXPO filings page.
EXPONENT INC (EXPO) reported insider equity transactions by Chief Executive Officer Catherine Corrigan. On 2026-08-17 she exercised 2,379 Non-Qualified Stock Options at an exercise price of $29.05 per share, receiving an equal number of common shares and fully using that option grant. On the same date she sold 1,707 common shares at $66.2776 per share in a transaction the company identifies as made under a Rule 10b5-1 trading plan, with the sale described as covering the option exercise price and related taxes.
Exponent Inc. reports that Chief Executive Officer Catherine Corrigan exercised options to acquire 12,665 shares of common stock on July 28, 2026 at an exercise price of $37.45 per share, converting a Non-Qualified Stock Option scheduled to expire on February 15, 2028.
Following the exercise, Corrigan directly holds 128,436 shares of Exponent common stock.
Exponent Inc. reported that CEO Catherine Corrigan exercised non-qualified stock options for 2,379 shares of common stock at $29.05 per share and on the same date sold 1,737 shares at $62.7776 per share to cover the option exercise price and taxes. After these trades, she directly held 115,771 common shares, and the transactions were effected under a Rule 10b5-1 trading plan.
Exponent Inc. CEO Catherine Corrigan exercised stock options to acquire 7,872 shares of common stock. The options were exercised at an effective price of $25.405 per share, converting an incentive stock option grant into common shares.
Following this exercise, Corrigan directly holds 115,129 shares of Exponent common stock. The derivative position tied to this option grant was reduced to zero, and there was no reported same-day sale, indicating an exercise-and-hold transaction. A footnote notes the stock option became exercisable in four equal annual installments.
Exponent Inc. President & CEO Catherine Corrigan reported an option exercise and related stock sales in Exponent Inc. common stock. On June 15, 2026, she exercised non-qualified stock options covering 5,605 shares at exercise prices of $29.05 and $25.405 per share.
On the same date, she executed open-market sales totaling 4,119 shares at an average price of $57.1263 per share to cover the option exercise price and taxes, according to the footnote. After these transactions, she directly holds 106,670 shares of Exponent common stock.
Exponent Inc. director Carol Lindstrom reported compensation-related equity activity and no open-market trades. She received a grant of 2,859 Restricted Stock Units (RSUs) that will cliff-vest on the day prior to the company’s next annual shareholder meeting. She also exercised 2,009 previously granted RSUs into 2,009 shares of Common Stock on a 1-for-1 basis, leaving no remaining RSUs from that prior grant. Following these transactions, she directly holds 9,405 shares of Common Stock. All transactions were recorded at a price of $0.00 per share, reflecting equity awards and a derivative conversion rather than market purchases or sales.
Exponent Inc. director George H. Brown received a grant of 2,859 Restricted Stock Units on June 4, 2026, which will cliff-vest before the company’s next annual shareholder meeting. On June 3, 2026, he also exercised 2,009 previously vested RSUs on a 1-for-1 basis into Common Stock, bringing his direct Common Stock holdings to 10,730 shares.
Exponent Inc director Karen A. Richardson reported equity compensation activity and updated holdings. She received a grant of 2,859 Restricted Stock Units (RSUs) that will cliff-vest on the day prior to the company’s next annual shareholder meeting, meaning all units vest at once.
She also exercised 2,009 previously vested RSUs into 2,009 shares of common stock on a 1-for-1 basis at no cash cost, leaving 2,009 common shares held directly. A separate entry shows 32,232 common shares held indirectly through a trust, reflecting additional ownership outside her personal account.
Exponent Inc director Debra Zumwalt reported routine equity compensation activity. On June 4, 2026, she received a grant of 2,859 Restricted Stock Units, which will cliff-vest before the company’s next annual shareholder meeting. On June 3, 2026, she exercised 2,009 RSUs into the same number of common shares on a 1:1 basis, bringing her direct common stock holdings to 31,830 shares.
Exponent Inc. director Paul R. Johnston exercised vested Restricted Stock Units into common stock in a routine compensation-related transaction. On June 3, 2026, 2,009 RSUs granted on June 5, 2025 converted into 2,009 shares of common stock on a 1-for-1 basis at no stated price.
Following the transaction, Johnston directly owns 62,940 shares of Exponent common stock. The filing shows an option/RSU exercise and conversion, with no open-market purchases or sales and no remaining RSU balance from this specific award.
Exponent Inc. Group Vice President James Bradley reported an open-market sale of 2,000 shares of Common Stock on May 26, 2026 at an average price of $57.465 per share. Following this transaction, he directly holds 1,105 shares of Exponent common stock.
Exponent Inc. Group Vice President Richard Reiss reported an open-market sale of 1,672 shares of Common Stock on May 19, 2026 at an average price of $58.6496 per share.
After this transaction, he directly holds 2,288 shares of Exponent common stock.
Exponent Inc. President & CEO Catherine Corrigan reported an option exercise and related share sales. On May 15, 2026, she exercised options for a total of 5,606 shares of common stock at strike prices of $29.05 and $25.405 per share, converting derivative awards into regular shares.
On the same date, she sold 4,194 shares of common stock in open-market transactions at an average price of $54.0595 per share. A footnote states these sales were made to cover the option exercise price and taxes, indicating a routine liquidity event rather than a purely discretionary sale. After these transactions, Corrigan directly owns 105,218 shares of Exponent common stock.
Exponent Inc.’s Group Vice President Joseph Rakow reported an open-market sale of company stock. On May 13, 2026, he sold 2,945 shares of Exponent common stock at an average price of $54.6601 per share. Following this transaction, his directly held common stock position reported in this filing was 0 shares.
Exponent Inc. Group Vice President Joseph Sala reported an open-market sale of Common Stock. On May 13, 2026, he sold 2,066 shares at $56.66 per share. Following this transaction, the filing shows Sala directly holding 0 shares of Exponent common stock.
Exponent Inc. President & CEO Catherine Corrigan reported a series of option exercises combined with share sales. On March 16 and April 15, she exercised options covering a total of 11,211 shares of common stock at exercise prices of $25.405 and $29.05 per share.
Across the same dates, she sold 7,821 shares in open-market transactions at prices around $67.49–$67.70 per share and retained the remainder. Following these transactions, Corrigan holds 104,359 shares of Exponent common stock directly.
Exponent Inc. vice president John Pye received new stock option awards. On April 6, 2026, he was granted an Incentive Stock Option for 6,008 shares and a Non-Qualified Stock Option for 14,992 shares, each with an exercise price of $66.56 per share.
The options become exercisable in four equal annual installments and are scheduled to expire on April 6, 2036. These awards are compensation-related grants, not open-market purchases or sales, and increase his direct derivative exposure to Exponent common stock.
SCHLENKER RICHARD L JR reported acquisition or exercise transactions in this Form 4 filing.
Exponent Inc. reported that EVP & Chief Financial Officer Richard L. Schlenker Jr. received a grant of 10,688 restricted stock units on March 13, 2026. Each unit represents a right to receive one share of common stock on a 1-for-1 basis. Following this compensation-related award, he holds 10,688 restricted stock units directly.
Sala Joseph reported acquisition or exercise transactions in this Form 4 filing.
Exponent Inc reported that Group Vice President Joseph Sala received a grant of 9,798 Restricted Stock Units on March 13, 2026. These RSUs are a form of stock-based compensation, with each unit convertible into one share of Exponent common stock on a 1-for-1 basis.
Following this award, Sala holds 9,798 RSUs directly, all tied to Exponent common stock. The grant was made at no cash cost per unit and reflects routine executive equity compensation rather than an open-market stock purchase or sale.
Exponent Inc reported that Group Vice President Maureen T. F. Reitman received a grant of 9,500 restricted stock units (RSUs) on March 13, 2026. Each RSU represents a right to receive one share of Exponent common stock, giving her 9,500 RSUs outstanding after this award. These units vest into common shares based on the company’s terms, with an exercise and expiration date in March 2030, and were granted at no cash cost to her as part of equity compensation.
Reiss Richard reported acquisition or exercise transactions in this Form 4 filing.
Exponent Inc reported that Group Vice President Richard Reiss received a grant of 2,970 restricted stock units on March 13, 2026. These RSUs represent the right to receive 2,970 shares of common stock on a 1-for-1 basis, as noted in the footnotes. Following this award, his reported derivative holdings in these RSUs total 2,970 units, reflecting routine equity-based compensation rather than any open-market buying or selling of shares.
Exponent Inc reported that Group Vice President Joseph Rakow received a grant of 10,688 restricted stock units on March 13, 2026. These RSUs represent a right to receive an equal number of shares of Exponent common stock on a 1-for-1 basis and are shown at a price of $0.00 because they are an equity award, not a market purchase. Following this grant, Rakow holds 10,688 RSUs directly, with an exercise and expiration date of March 13, 2030.
Exponent Inc reported that VP Global Offices & Innovation John Pye received a grant of 5,938 restricted stock units (RSUs) on March 13, 2026. These RSUs are a compensation-related award with a stated price of $0.00 per unit and each unit is exchangeable on a 1-for-1 basis into shares of common stock.
Following this award, Pye holds 5,938 RSUs directly. The RSUs relate to an equal number of underlying shares of common stock and are scheduled with an exercise and expiration date of March 13, 2030, indicating a long-term equity incentive rather than an open-market purchase.
Kundert Brian reported acquisition or exercise transactions in this Form 4 filing.
Exponent Inc. reported that Chief Human Resources Officer Brian Kundert received a grant of 3,564 restricted stock units on March 13, 2026. These units represent a 1-for-1 right to receive shares of common stock, typically as part of long-term equity compensation.
Following this award, he is reported as holding 3,564 restricted stock units directly. The transaction is recorded as a grant or award, not an open-market purchase or sale, and therefore reflects standard executive compensation rather than a discretionary trade.
Exponent Inc reported that Group Vice President James Bradley A received a grant of 4,454 Restricted Stock Units (RSUs) on March 13, 2026. These RSUs represent rights to receive an equal number of shares of common stock on a 1-for-1 basis.
The grant is a compensation-related award at no purchase cost, rather than an open-market transaction. Following this award, Bradley holds 4,454 RSUs directly. The RSUs are scheduled with an exercise and expiration date of March 13, 2030, indicating the expected settlement period for the underlying common shares.
Exponent Inc. President and CEO Catherine Corrigan received a grant of 17,814 restricted stock units on March 13, 2026. These RSUs are a form of equity compensation and are directly owned. Each unit is exchangeable on a 1-for-1 basis into Exponent common stock. Following this award, Corrigan holds 17,814 RSUs tied to an equivalent number of underlying common shares, with a stated conversion and expiration date of March 13, 2030.
Exponent Inc Group Vice President Richard Reiss reported routine equity compensation activity. He exercised 2,120 Restricted Stock Units granted on March 11, 2022, converting them into an equal number of common shares on a 1:1 basis. To cover related tax obligations, the company withheld 958 common shares at a value of $70.03 per share. After these transactions, Reiss directly holds 3,960 shares of Exponent common stock, indicating a net increase in his ownership from this award vesting and tax withholding event.
Exponent Inc.’s EVP & Chief Financial Officer Richard L. Schlenker Jr. exercised vested equity awards and had shares withheld for taxes. He converted 7,630 Restricted Stock Units granted on March 11, 2022 into 7,630 shares of Common Stock on a 1:1 basis. To satisfy tax withholding obligations, 3,694 Common Stock shares were withheld by the company, leaving him with 230,351 Common Stock shares held directly after these transactions. These actions represent routine equity compensation vesting and related tax settlement rather than open-market buying or selling.
EXPONENT INC Group Vice President Joseph Sala reported compensation-related equity activity. On March 11, 2026, he exercised 3,180 Restricted Stock Units granted on March 11, 2022, converting them into 3,180 shares of Common Stock on a 1:1 basis.
To cover tax withholding obligations, 1,114 of these shares were withheld by the company at a value of $70.03 per share, leaving Sala with 2,066 shares of Common Stock held directly after the transactions. The filing shows no remaining derivative (RSU) position from this grant.
Exponent Inc. Group Vice President Maureen T. F. Reitman exercised restricted stock units and settled related taxes in shares. On March 11, 2026, 5,510 vested Restricted Stock Units granted on March 11, 2022 were converted into 5,510 shares of Common Stock on a 1:1 basis.
To satisfy tax withholding obligations, 1,756 shares of Common Stock were withheld by the company at $70.03 per share. After these transactions, Reitman directly owned 39,226 shares of Exponent Common Stock, reflecting a routine compensation-related vesting and tax withholding event rather than an open-market sale.
Exponent Inc. Group Vice President Joseph Rakow exercised vested equity awards and received new common shares. He converted 5,298 Restricted Stock Units, granted on March 11, 2022, into 5,298 shares of Common Stock on a 1:1 basis. To cover tax withholding obligations, the company withheld 2,353 shares at a value of $70.03 per share, leaving Rakow with 2,945 shares of Common Stock held directly after the transactions. These movements reflect routine equity compensation vesting and associated tax withholding, rather than open-market buying or selling.
Exponent Inc. executive John Pye reported routine equity compensation activity involving restricted stock units and common shares. On March 11, 2026, 5,934 vested restricted stock units were converted into 5,934 shares of common stock on a 1:1 basis, reflecting the vesting of awards originally granted on March 11, 2022.
To cover tax withholding obligations tied to this vesting, 2,384 common shares were withheld by the company at a price of $70.03 per share, a tax-related disposition rather than an open-market sale. After these transactions, Pye directly holds 29,131 shares of Exponent common stock.
Exponent Inc. Group Vice President James Bradley reported routine equity compensation activity. On March 11, 2026, 4,664 vested Restricted Stock Units granted on March 11, 2022 converted into 4,664 shares of common stock on a 1:1 basis. To satisfy tax withholding obligations, the company withheld 1,559 of these shares at a price of $70.03 per share. Bradley retained 3,105 common shares directly following the transactions. The withholding is a tax payment mechanism, not an open-market sale.
Exponent Inc. President & CEO Catherine Corrigan reported routine equity compensation activity. On March 11, 2026, she exercised vested Restricted Stock Units covering 12,716 shares of common stock on a 1:1 basis, converting them into 12,716 shares of common stock at a stated price of $0.00 per share.
To satisfy tax withholding obligations tied to this vesting, 6,156 common shares were withheld by the company at a reference price of $70.03 per share, according to the filing footnotes. After these transactions, Corrigan directly holds 100,969 shares of Exponent common stock. This filing reflects compensation-related vesting and associated tax withholding, not an open-market purchase or sale.
Exponent Inc. Group Vice President Maureen T. F. Reitman reported a bona fide gift of 140 shares of Exponent common stock. The gift was recorded at a price of $0.00 per share and is classified as a disposition by gift, not an open-market sale. After this transaction, she directly owns 35,472 shares of Exponent common stock.
Corrigan Catherine reported acquisition or exercise transactions in this Form 4 filing.
Exponent Inc. President and CEO Catherine Corrigan reported awards of stock options, increasing her potential equity exposure to the company. She received 1,425 Incentive Stock Options and 27,075 Non-Qualified Stock Options, both granted at no cost as part of her compensation.
According to the disclosure, each stock option grant becomes exercisable in four equal annual installments, meaning the rights vest gradually over four years rather than all at once. These are options giving her the right to buy shares in the future; they are not immediate stock purchases or sales.
SCHLENKER RICHARD L JR reported acquisition or exercise transactions in this Form 4 filing.
Exponent Inc EVP & CFO Richard L. Schlenker Jr. reported awards of stock options on February 20, 2026. He received 1,425 incentive stock options and 17,575 non-qualified stock options, each representing rights to buy Exponent shares. According to the footnotes, these options become exercisable in four equal annual installments.
Exponent Inc. President & CEO Catherine Corrigan exercised two non-qualified stock options, acquiring 3,226 and 2,380 shares of common stock at exercise prices of $25.4050 and $29.0500. She then sold a total of 3,920 shares of common stock, including 2,218 shares at $67.1646 and 1,702 shares at $67.1378, with the stock sale used to cover the option exercise price and taxes as noted in the footnotes.
Exponent Inc.'s Executive Vice President and Chief Financial Officer, Richard L. Schlenker Jr., reported an option exercise that increased his direct common stock holdings. On February 11, 2026, he exercised an Incentive Stock Option for 4,230 shares at an exercise price of $23.63 per share, converting the derivative position into common stock. Following this transaction, he directly owned 226,109 shares of Exponent common stock.
Exponent Inc.'s VP Global Offices & Innovation, John Pye, reported selling a total of 4,000 shares of common stock in open-market transactions on February 10, 2026. The sales occurred in two trades: 341 shares at $75.935 and 3,659 shares at $75.9781 per share.
Following these sales, Pye directly owns 25,204 shares of Exponent common stock. All reported holdings are listed as directly owned, with no indirect ownership disclosed in this filing.
Catherine Corrigan, President & CEO of Exponent Inc., exercised 2,380 non-qualified stock options on January 15, 2026 at an exercise price of $29.05 per share, receiving common stock. That same day she sold 1,663 shares at $72.5158 per share and now directly holds 92,723 shares of Exponent common stock.
Exponent Inc. insider activity: President & CEO and director Catherine Corrigan reported exercising an incentive stock option for 7,872 shares of Exponent common stock on 12/16/2025 at an exercise price of $25.405 per share. After this transaction, she beneficially owns 92,006 shares of common stock directly. The derivative security reported is an incentive stock option covering 7,872 shares of common stock, with the option described as becoming exercisable in four equal annual installments, and 7,872 derivative securities remaining beneficially owned following the reported transaction.
Exponent Inc. President & CEO and director Catherine Corrigan reported an insider stock transaction. On 12/15/2025, she exercised a non-qualified stock option for 3,225 shares of common stock at an exercise price of $25.405 per share, increasing her directly held shares. On the same day, she sold 3,225 shares of common stock at a price of $70.7387 per share. After these transactions, she directly owned 84,134 shares of Exponent common stock and held 16,128 non-qualified stock options.
Exponent Inc. (EXPO) President & CEO and director Catherine Corrigan reported stock option exercises and related share sales. On 11/17/2025, she exercised non-qualified stock options for 3,225 shares at $25.405 and 2,380 shares at $29.05, converting them into common stock. She then sold 3,225 shares at $70.205 and 1,675 shares at an average price of $70.7387, with the filing noting that one sale was to cover the option exercise price and taxes. After these transactions, she directly owned 84,134 shares of Exponent common stock, and still held options for 19,353 and 19,038 shares that remain outstanding.
Exponent, Inc. (EXPO) reported insider activity by President & CEO and Director Catherine Corrigan on 10/15/2025. She exercised 3,226 options at $25.405 and 2,380 options at $29.05, then sold 3,226 shares at $66.84 and 1,704 shares at $66.7926. A footnote states the sale was to cover the option exercise price and taxes.
Following these transactions, she directly owned 83,429 shares. The options noted are non‑qualified stock options that vest in four equal annual installments.